FOXO TECHNOLOGIES SEC Filings

Welcome to our dedicated page for FOXO TECHNOLOGIES SEC filings (Ticker: FOXO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The FOXO Technologies Inc. (FOXO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including Current Reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. These filings describe material events affecting FOXO’s healthcare, biospecimen and biotechnology businesses, as well as its capital structure and governance.

Corporate actions and capital structure are a recurring focus of FOXO’s 8-K filings. The company reports amendments to its Certificate of Incorporation to increase authorized shares of Class A common stock and preferred stock, as well as Amended and Restated Certificates of Designation for its Series A, B, C, D and E preferred stock. These documents outline changes to conversion prices, voting rights, and dividend terms, and explain how preferred stock relates to FOXO’s acquisition vehicle, FOXO Acquisition Corporation (FAC).

Filings also cover equity and listing-related events, such as the approval of a 1-for-1.99 reverse stock split of FOXO’s Class A common stock aimed at supporting NYSE American continued listing requirements, and subsequent disclosure that NYSE Regulation initiated proceedings to delist FOXO’s common stock due to minimum price rules, with trading moving to the OTC market under the symbol FOXO.

Investors can review transaction-related filings, including Forms 8-K describing the stock purchase agreement and closing of the acquisition of Vector BioSource, Inc. These filings summarize consideration paid in cash, Series E Cumulative Redeemable Secured Preferred Stock and warrants, and explain conditions such as revenue-based earn-out provisions and funding commitments for Vector’s growth budget.

FOXO’s 8-Ks also address governance and control matters, including written consents by a majority stockholder (Rennova Health, Inc.) approving increases in authorized share capital and the election of directors, as well as the appointment of a Chief Financial Officer and the non-binding ratification of the company’s independent registered public accounting firm.

On Stock Titan, FOXO filings are supplemented with AI-powered summaries that highlight key terms in these documents, helping readers quickly understand amendments to preferred stock designations, reverse stock split mechanics, acquisition structures and shareholder approvals. Users can use this page to locate FOXO’s 8-Ks that reference press releases, reverse stock split details, preferred stock amendments and other material corporate events, and to track how these regulatory disclosures relate to the company’s healthcare and biotechnology operations.